Dantrolene, an intracellularly acting skeletal muscle relaxant, inhibits Ca release from the sarcoplasmic reticulum during excitation-contraction coupling by an unknown mechanism. The drug is used to treat malignant hyperthermia, a genetic sensitivity to volatile anesthetics which results in the massive release of intracellular Ca from affected skeletal muscle. We hypothesize that determination of the site of action of dantrolene will lead to further understanding of the regulation of sarcoplasmic reticulum calcium release. We report the identification of specific dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum using a rapid filtration binding assay for [H]dantrolene. The binding isotherm in the heavy sarcoplasmic reticulum fraction indicates a single binding site with a K of 277 ± 25 nM and a B of 13.1 ± 1.5 pmol/mg of protein. Pharmacological specificity is characterized by inhibition of [H]dantrolene binding with unlabeled dantrolene, or azumolene, a physiologically active congener, but not with aminodantrolene, which is physiologically inactive. Drug binding is maximal at pH 6.5-7.5, requires no Ca or Mg, and is inhibited by salt concentrations above 100 mM. [H]Dantrolene binding is greatest in the sarcoplasmic reticulum, which contains the ryanodine receptor, the primary calcium release channel. No binding is detected in the fractions enriched for sarcolemma or transverse tubules. We suggest that dantrolene inhibits calcium release from the sarcoplasmic reticulum by either direct or indirect interaction with the ryanodine receptor.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				G. Cherednichenko, C. W. Ward, W. Feng, E. Cabrales, L. Michaelson, M. Samso, J. R. Lopez, P. D. Allen, and I. N. Pessah Enhanced Excitation-Coupled Calcium Entry in Myotubes Expressing Malignant Hyperthermia Mutation R163C Is Attenuated by Dantrolene Mol. Pharmacol., April 1, 2008; 73(4): 1203 - 1212. [Abstract] [Full Text] [PDF]

				M. Shigeto, M. Katsura, M. Matsuda, S. Ohkuma, and K. Kaku Nateglinide and Mitiglinide, but Not Sulfonylureas, Induce Insulin Secretion through a Mechanism Mediated by Calcium Release from Endoplasmic Reticulum J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 1 - 7. [Abstract] [Full Text] [PDF]

				T. Murayama, T. Oba, S. Kobayashi, N. Ikemoto, and Y. Ogawa Postulated role of interdomain interactions within the type 1 ryanodine receptor in the low gain of Ca2+-induced Ca2+ release activity of mammalian skeletal muscle sarcoplasmic reticulum Am J Physiol Cell Physiol, June 1, 2005; 288(6): C1222 - C1230. [Abstract] [Full Text] [PDF]

				S. Kobayashi, M. L. Bannister, J. P. Gangopadhyay, T. Hamada, J. Parness, and N. Ikemoto Dantrolene Stabilizes Domain Interactions within the Ryanodine Receptor J. Biol. Chem., February 25, 2005; 280(8): 6580 - 6587. [Abstract] [Full Text] [PDF]

				O. Langeron, C. Coirault, S. Fratea, G. Orliaguet, P. Coriat, and B. Riou The Effects of Dantrolene on the Contraction, Relaxation, and Energetics of the Diaphragm Muscle Anesth. Analg., August 1, 1999; 89(2): 466 - 466. [Abstract] [Full Text] [PDF]

				E. D. Buck, W. G. Lachnit, and I. N. Pessah Mechanisms of delta -Hexachlorocyclohexane Toxicity: I. Relationship Between Altered Ventricular Myocyte Contractility and Ryanodine Receptor Function J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 477 - 485. [Abstract] [Full Text]

				H. Westerblad, A. J Dahlstedt, and J. Lannergren Mechanisms underlying reduced maximum shortening velocity during fatigue of intact, single fibres of mouse muscle J. Physiol., July 1, 1998; 510(1): 269 - 277. [Abstract] [Full Text] [PDF]

				B. R. Fruen, J. R. Mickelson, and C. F. Louis Dantrolene Inhibition of Sarcoplasmic Reticulum Ca2+ Release by Direct and Specific Action at Skeletal Muscle Ryanodine Receptors J. Biol. Chem., October 24, 1997; 272(43): 26965 - 26971. [Abstract] [Full Text] [PDF]

				R. Zucchi and S. Ronca-Testoni The Sarcoplasmic Reticulum Ca2+ Channel/Ryanodine Receptor: Modulation by Endogenous Effectors, Drugs and Disease States Pharmacol. Rev., March 1, 1997; 49(1): 1 - 52. [Abstract] [Full Text] [PDF]

				F. Zhao, P. Li, S. R. W. Chen, C. F. Louis, and B. R. Fruen Dantrolene Inhibition of Ryanodine Receptor Ca2+ Release Channels. MOLECULAR MECHANISM AND ISOFORM SELECTIVITY J. Biol. Chem., April 20, 2001; 276(17): 13810 - 13816. [Abstract] [Full Text] [PDF]